Yi-Lun Wang
1 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Ruxolitinib as add-on Therapy in Steroid-refractory Graft-vs-host Disease (NCT05663827) | Yi-Lun Wang | 2019-01-01 |
Track Yi-Lun Wang automatically
Every clearance here is in the API, with alerts when new ones post.